Isolation and preliminary microheterogeneity studies of lecithin-cholesterol acyltransferase in plasma from individual patients infected with Schistosomiasis mansoni

International Hepatology Communications

Volumn 6, Issue 6, 1997, Pages 300-305

  De Menezes Lima, Vera Lucia ^b   Cannizzaro, Helia Maria ^b   Owen, James S ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

high performance liquid chromatography; immunoaffinity chromatography; isoelectric focussing; isoforms; liver disease; serum glycoprotein

Indexed keywords

PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME GLYCOSYLATION; ENZYME PURIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOAFFINITY CHROMATOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

EID: 0344760521     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00360-5     Document Type: Article

References (12)

1. [1] Dolphin PJ. Lipolytic enzymes and the role of apolipoproteins in the regulation of their activity. In: Rosseneu, M., ed. Structure and Function of Apolipoproteins. Boca Raton: CRC Press Inc., 1992; 295-362.
2. [2] Owen JS, Rafique S, Osman E, Burroughs AK. Ability of S-adenosyl-L-methionine to ameliorate lipoprotein-induced membrane lipid abnormalities and cellular dysfunctions in human liver disease. Drug Invest 1992; 4(Suppl. 4): 22-40.
3. [3] Owen JS, Gillett MPT. Lecithin: cholesterol acyltransferase deficiency associated with hepatic schistosomiasis mansoni. Scand J Clin Lab Invest 1978; 38 (Suppl. 150): 194-198.
4. [4] Horton RC, Owen JS. LCAT activity as a prognostic liver function test. Lancet 1990; 336: 249-250.
5. [5] Shimada M, Katasuhiko Y, Makowka L, Kakizoe S, Van Thiel DH, Starzl TE. Significance of lecithin:cholesterol acyl transferase activity as a prognostic indicator of early allograft function in clinical liver transplantation. Transplantation 1989; 48: 600-603.
6. [6] Collet X, Fielding CJ. Effects of inhibitors of N-linked oligosaccharide processing on the secretion, stability, and activity of lecithin:cholesterol acyltransferase. Biochemistry 1991; 30: 3228-3234.
7. [7] Qu S-J, Fan HZ, Blanco-Vaca F, Pownall HJ. Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase. Biochemistry 1993; 32: 8732-8736.
8. [8] Turner GA. N-Glycosylation of serum proteins in disease and its investigation using lectins. Clin Chim Acta 1992; 208: 149-171.
9. [9] Gillett MPT, Owen JS. Cholesterol esterifying enzymes lecithin:cholesterol acyltransferase (LCAT) and acylcoenzyme A: cholesterol acyltransferase (ACAT). In: Converse C, Skinner RE, eds. Lipoprotein Analysis. Oxford: IRL Press. 1992; 187-201.
10. [10] Lima VLM, Harry DS, Owen JS, McIntyre N. Polyclonal antibodies to human lecithin:cholesterol acyltransferase. Biochem. Soc. Trans. 1987; 15: 477-478.
11. [11] Lima VLM, Harry DS, McIntyre N, Owen JS, Chaves MEC. Characterization and potential uses of rabbit polyclonal antibodies against human plasma lecithin-cholesterol acyltransferase. Braz. J. Med. Biol. Res. 1996; 29: 957-968.
12. [12] Holmquist L, Bjellqvist B. Microheterogeneity of human plasma lecithin:cholesterol acyltransferase examined by isoelectric focusing in immobilized pH gradients. Electrophoresis 1988; 9: 580-582.